Pharmaceuticals news FT.com

AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech

Partnership gives group access to CSPC’s AI platform for discovering and optimising treatments

Jun 13, 2025 - 13:45
 0
AstraZeneca signs $5.2bn deal to develop drugs for chronic disease with Chinese biotech
Partnership gives group access to CSPC’s AI platform for discovering and optimising treatments
Read More

Tags:

Previous Article

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

Next Article

More than 70 nutrition scientists call for freedom from censorship at NIH

Related Posts

NHS signs deal with Scancell in ambitious skin cancer trial

NHS signs deal with Scancell in ambitious skin cancer t...

May 12, 2025  0

GSK buys Boston Pharmaceuticals’ new liver disease drug for up to $2bn

GSK buys Boston Pharmaceuticals’ new liver disease drug...

May 14, 2025  0

AstraZeneca ‘committed’ to US manufacturing as profits rise

AstraZeneca ‘committed’ to US manufacturing as profits ...

May 12, 2025  0